Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 4,268 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ADM Clear all

Conditions: Unsafe Sex, Risk Reduction
Interventions: PROJECT POWER, Power Health; Behavioral
Lead sponsor: Nova Southeastern University; Other
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 211 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atrial Fibrillation
Interventions: General Anesthesia with endotracheal tube, General Anesthesia with laryngeal mask airway; Device
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: B-cell Lymphoma, Burkitt Lymphoma
Interventions: Etoposide, Doxorubicin, Cyclophosphamide, Rituximab, Vincristine, Prednisone, Loncastuximab Tesirine 0.075 mg/kg by IV, Loncastuximab tesirine 0.12 mg/kg by IV, Loncastuximab tesirine 0.15 mg/kg by IV; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Dallas, Texas • Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Cystic Fibrosis
Interventions: Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge, Olfactory Function Testing, Survey Completion; Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions: Bevacizumab, Everolimus, Laboratory Biomarker Analysis, Pegylated Liposomal Doxorubicin Hydrochloride; Biological · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Autism Spectrum Disorder
Interventions: Autism Pupil Screen (APS) Detect PLR Assessment #1, Modified Checklist for Autism in Toddlers, Revised with Follow-up (M-CHAT/R-F), Social Responsiveness Scale, Second Edition (SRS-2), Autism Diagnostic Observation Schedule, Second Edition (ADOS-2), Mullen Scales of Early Learning (MSEL), Adaptive Behavior Assessment System, Third Edition (ABAS-3), Autism Pupil Screen (APS) Detect PLR Assessment #2, Autism Pupil Screen (APS) Detect Assessment #3, Well-child check; Device · Other · Diagnostic Test + 1 more
Lead sponsor: Schweitzer Engineering Laboratories; Industry
Eligibility: 24 Months to 60 Months
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Lewiston, Idaho • Moscow, Idaho • Pullman, Washington

Conditions: Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions: Eribulin, Adriamycin, Cyclophosphamide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
Interventions: GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab; Drug
Lead sponsor: GI Innovation, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more

Conditions: Caregiver Burden, Behavioral and Psychiatric Symptoms of Dementia, Depressive Symptoms, Quality of Life, Psychological Flexibility, Sleep Quality, Positive Aspects of Caregiving
Interventions: Acceptance and Commitment Therapy; Behavioral
Lead sponsor: Utah State University; Other
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Logan, Utah

Conditions: Breast Cancer
Interventions: Focused Microwave Thermotherapy, Chemotherapy (control); Device · Drug
Lead sponsor: Medifocus, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Substance Related Disorders, Mental Illness
Interventions: Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition), Getting To Outcomes; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 227 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 4
States / cities: Denver, Colorado • Washington D.C., District of Columbia • Bedford, Massachusetts + 1 more

Conditions: Overweight and/or Obesity
Interventions: AGILE Intervention, Chatbot; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 39 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Sickle Cell Disease
Interventions: General Tutoring, Memory Training; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 8 Years to 18 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Interventions: Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Idarubicin, Idelalisib, In Vitro Kinase Inhibitor Assay, Leucovorin Calcium, Methotrexate, Methylprednisolone Sodium Succinate, Ponatinib Hydrochloride, Rituximab, Ruxolitinib Phosphate, Sorafenib Tosylate, Sunitinib Malate, Vincristine Sulfate; Drug · Device · Biological
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 64 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Soft Tissue Sarcoma
Interventions: GPX-150 for Injection; Drug
Lead sponsor: Gem Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Chicago, Illinois • Iowa City, Iowa • St Louis, Missouri + 1 more

Conditions: The Pk of IV Ketamine in Children With Heart Disease
Interventions: ketamine hydrochloride; Drug
Lead sponsor: Stanford University; Other
Eligibility: Up to 17 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Palo Alto, California • Denver, Colorado

Conditions: Asthma
Interventions: Multi-Component Technology Based Intervention; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 29 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Lumbar Disc Herniation, Radiculopathy
Interventions: Rehabilitation following lumbar disc surgery (discectomy); Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Tobacco Use Disorder
Interventions: Tobacco Use Disorder, Standard Web-based intervention; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 792 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non Hodgkin Lymphoma, Heart; Functional Disturbance, Hodgkin Lymphoma, Quality of Life, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions: Exercise with Trainerize application, Cardiopulmonary exercise testing, MRI scan, Quality of Life Questionnaires, Cognitive and Brain Function Questionnaires, Blood draws; Other · Diagnostic Test · Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 85 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Winston-Salem, North Carolina • Richmond, Virginia

Conditions: Focal Brain Lesion, Focal Lesions, fMRI
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Motor Vehicle Injury
Interventions: Modular child restraint; Other
Lead sponsor: Minnesota HealthSolutions; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: bortezomib, melphalan, pegylated liposomal doxorubicin hydrochloride; Drug
Lead sponsor: Herbert Irving Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: San Francisco, California • New York, New York

Conditions: Cesarean Delivery, General Anesthesia
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 15 Years to 55 Years · Female only
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 34
States / cities: Little Rock, Arkansas • San Francisco, California • Stanford, California + 29 more

Search by objective public record fields.

Project Power: An HIV Risk Reduction Intervention for Black Men Who Have Sex With Men and Women (BMSM/W)

General Anesthesia With ETT vs LMA in Patients Undergoing Ablation for Atrial Fibrillation

Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies

Impact of Highly Effective Modulator Therapy on the Cystic Fibrosis Microbiome

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

Effectiveness of the Autism Pupil Screen (APS) Detect Pupillometer for Identifying Autism Spectrum Disorder (ASD) in Routine Healthcare

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Acceptance Commitment Therapy for Caregivers of People with Memory Loss

Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors

MISSION-Vet HUD-VASH Implementation Study

Piloting a Generative Artificial Intelligence Chatbot in a Mobile Weight Loss Program

A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma

Pharmacokinetics of Ketamine in Infants and Children

Detroit Young Adult Asthma Project

Rehabilitation Following Lumbar Disc Surgery

LGBT Internet Based Smoking Treatment - 1

Improving Exercise Capacity With a Tailored Physical Activity Intervention

Top-Down Attentional Control of Visual-Processing

Swivel Convertible Child Safety Seat to Improve Usage

Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma

The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry